US · Healthcare · Biotechnology
EPS came in at -2.13 against a street estimate of -0.16 — a miss of 1231.2%.
Analysts rate Parabilis Medicines, Inc. Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $41.75.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 23.42% |
| FMR Inc | 8.33% |
| ARCH VENTURE CORP | 5.19% |
| venBio Partners LLC | 4.26% |
| Alphabet Inc | 3.98% |
| Nextech Invest, Ltd. | 3.77% |
| Cormorant Asset Management, LLC | 3.74% |
| Regeneron Pharmaceuticals Inc | 3.37% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 PARABILIS MEDICINES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Parabilis Medicines, Inc. (Nasdaq: PBLS) • Headquarters: Cambridge, Massachusett | 2026-09-15 |
| Board / officer change · Q3 2026 PARABILIS MEDICINES, INC. - 8-K SUMMARY HEADLINE NUMBERS • No financial figures disclosed in this 8-K filing • Company: Parabilis Medicines, Inc. (ti | 2026-09-02 |
| Board / officer change · Q3 2026 PARABILIS MEDICINES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 8 to 9 directors • New director granted stock options to purcha | 2026-08-25 |
| Quarterly report · Q2 2026 PARABILIS MEDICINES, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $1,087.1 million in cash and cash equivalents as of June 30, 20 | 2026-08-13 |
| Results announced · Q3 2026 PARABILIS MEDICINES - Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $1.1 billion in cash, cash equivalents and marketable securities a | 2026-08-13 |
| Material agreement · Q2 2026 PARABILIS MEDICINES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company completed Initial Public Offering (IPO) on June 11, 2026 • Raised $75 million fro | 2026-06-11 |
Readable in the app.
| Announcement | Date |
|---|---|
| Strategic research collaboration with Regeneron on Antibody-Helicon Conjugates Parabilis Medicines, a clinical-stage biotech company, reported strong Q2 2026 results with major business developments. The company successfully completed an IPO raising $770.5M and ended t | 2026-08-13 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Parabilis Medicines, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.